@article{ee29bdbc456643cd8e49c2d00fa4d4b2,
title = "Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis",
author = "Roselie Achten and Daphne Bakker and Lieneke Ariens and Amanda Lans and Judith Thijs and \{van der Schaft\}, Jorien and \{de Boer\}, Joke and Deepak Balak and \{de Graaf\}, Marlies and \{van Luijk\}, Chantal and \{de Bruin-Weller\}, Marjolein",
note = "Funding Information: Patients included in this manuscript participated in the BioDay registry sponsored by Sanofi Genzyme.Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie ; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. ",
year = "2021",
month = mar,
doi = "10.1016/j.jaip.2020.09.042",
language = "English",
volume = "9",
pages = "1389--1392.e2",
journal = "The journal of allergy and clinical immunology. In practice",
issn = "2213-2201",
publisher = "American Academy of Allergy, Asthma and Immunology",
number = "3",
}